The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Novel immunotherapy and small molecule inhibitor combinations
Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, provides an overview of immunotherapy and small molecule inhibitor regimens for the treatment of metastatic non-small cell lung cancer (NSCLC). Targeting DNA damage response pathways with PARP and ATR inhibitors have been promising, especially with data from the Phase II HUDSON study (NCT03334617) , which assessed durvalumab with olaparib or ceralasertib. Encouraging activity was observed, particularly in ATM deficient patients receiving durvalumab and ceralasertib. Additional therapies of interest include cabozantinib, a MET inhibitor and is being assessed in the COSMIC-021 trial (NCT03170960), sitravatinib and bemcentinib, a receptor tyrosine kinases (RTK) and AXL inhibitor respectively. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
